Latest Research News on Atorvastatin: Nov – 2019

Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia

This double-blind procedure to guage semipermanent effectivity associate degreed safety of lipid-lowering medicine was performed in thirty one community- and university-based analysis centers within the USA to directly compare a replacement 3-hydroxy-3-methylglutaryl-coenzyme A enzyme matter (reductase inhibitor) to an accepted drug of this category in patients with moderate hypercholesteremia. Participants remained on a cholesterol-lowering diet throughout the study. One thousand cardinal patients were irregular to receive lipid-lowering medicine ten mg, lipid-lowering medicine twenty mg, or placebo. At sixteen weeks the placebo cluster was irregular to either lipid-lowering medicine or lipid-lowering medicine treatment. At twenty two weeks, patients WHO had not met lipoprotein (LDL) sterol target levels doubled the dose of enzyme matter. effectivity analysis was mean p.c modification from baseline in cholesterol, triglycerides, total sterol, high-density-lipoprotein sterol, and apolipoprotein B (apoB). Safety profiles as determined by modification from baseline in laboratory evaluations, ophthalmologic parameters, and coverage of adverse events were similar for the two enzyme inhibitors. [1]

Clinical Pharmacokinetics of Atorvastatin

Hypercholesterolaemia could be a risk issue for the event of hardening of the arteries} disease. Lipitor lowers plasma LDL (LDL) sterol levels by inhibition of 5-hydroxy-3-methylglutaryl-coenzyme A reductase. The mean dose-response relationship has been shown to be log-linear for Lipitor, however plasma concentrations of Lipitor acid and its metabolites don’t correlate with LDL-cholesterol reduction at a given dose. [2]

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

BACKGROUND: Statins cut back the incidence of strokes among patients at hyperbolic risk for vas disease; whether or not they reduce the danger of stroke when a recent stroke or transient ischaemic attack (TIA) remains to be established.

METHODS: we have a tendency to indiscriminately allotted 4731 patients United Nations agency had had a stroke or transient ischemic attack among one to 6 months before study entry, had LDL (LDL) steroid alcohol levels of one hundred to one hundred ninety mg per metric capacity unit (2.6 to 4.9 mmol per liter), and had no illustrious coronary cardiopathy to double-blind treatment with eighty mg of statin per day or placebo. the first finish purpose was a primary nonfatal  or fatal stroke. [3]

Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential

Atorvastatin, a well-liked possibility for lipoidemia exhibits the matter of poor stomachic solubility and low absolute bioavailability (12%) at the side of higher pre-systemic clearance (>80%). Therefore, to avoid these limitations, statin drug nanocrystals were ready mistreatment poloxamer-188 as stabilizer via air mass blending technique followed by drying up. numerous variables like drug to poloxamer-188 magnitude relation, blending cycle, blending pressure, sort and concentration of cryoprotectant were optimized to attain uniform nanosized crystals with sensible dispersibility. Solid state characterization by ATR-FTIR and DSC unconcealed no incompatible chemical science interaction between drug and excipients in formulation whereas DSC and PXRD put together verified the reduced crystallinity of drug in nanocrystals. [4]

Formulation and Evaluation of Pluronic F127 Thermosetting Gels Containing Atorvastatin Calcium as Novel Ophthalmic Delivery Systems

Aims: This study aims to formulate and valuate ophthalmic thermo-sensitive gels containing lipid-lowering medicine atomic number 20. the key drawback of the drug is poor water solubility, and thus the ocular bioavailability, complexation with cyclodextrin is an endeavor to resolve this drawback. The formulations based mostly in the main on Pluronic F127 alone or combined with alternative viscosity-increasing polymers.

Methodology: lipid-lowering medicine atomic number 20 the proved  effective medicinal drug agent utilized in ocular diseases was ready and defined within the sort of hydroxypropyl beta-cyclodextrin advanced. during this study, the likelihood to formulate thermoset gels containing either the free drug, drug-cyclodextrin physical mixture or advanced was investigated by victimisation heat sensitive polymers pluronic F127 alone or combined with alternative viscosity-increasing polymers like alkyl polysaccharide, PVP K25. [5]

Reference

[1] Group, A.S., Davidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkena, R., Fayyad, R. and Black, D., 1997. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. The American journal of cardiology, 79(11), (Web Link)

[2] Lennernäs, H., 2003. Clinical pharmacokinetics of atorvastatin. Clinical pharmacokinetics, 42(13), (Web Link)

[3] Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355(6), (Web Link)

[4] Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential
Manu Sharma & Isha Mehta
Scientific Reports volume 9, Article number: 16105 (2019) (Web Link)

[5] Girgis, G. N. S. (2018) “Formulation and Evaluation of Pluronic F127 Thermosetting Gels Containing Atorvastatin Calcium as Novel Ophthalmic Delivery Systems”, Ophthalmology Research: An International Journal, 9(3), (Web Link)

Leave a Reply

Your email address will not be published. Required fields are marked *